Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776

Topoisomerase I (Topo I) is a recognized target for ovarian, lung, and colorectal cancer therapy. The FDA-approved camptothecin (CPT) Topo I inhibitors, topotecan and irinotecan are labile and their effects are rapidly reversible. The indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Holleran, Julianne L., Parise, Robert A., Yellow-Duke, Archibong E., Egorin, Merrill J., Eiseman, Julie L., Covey, Joseph M., Beumer, Jan H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2865235/
https://ncbi.nlm.nih.gov/pubmed/20236781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2010.02.020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares